Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Retatrutide: a triple incretin receptor agonist for obesity management

Ray, Avik · 2023 · Expert Opinion on Investigational Drugs

Abstract

INTRODUCTION: Obesity treatment is evolving rapidly with the emergence of agents targeting incretin receptors. Retatrutide, a triple agonist of these receptors, shows promise in obesity management. AREAS COVERED: Retatrutide, in phase-2 trials, exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM). In non-T2DM individuals, it produced substantial weight loss and improved glucose levels, albeit with gastrointestinal side effects. The role of glucagon receptor agonism in the management of heart failure and its potential impact on eating patterns have also been covered in this article. EXPERT OPINION: Although the reductions in HbA1c and dose-dependent weight loss among individuals with T2DM were significantly more for higher doses of retatrutide, it needs to be observed that the active comparator was dulaglutide, which is not approved for the treatment of obesity, at a dose of 1.5 mg, which is much lower than the highest approved dose of 4.5 mg. Dose-dependent increase in heart rate and incidents of mild to moderate cardiac arrythmias raise cardiovascular safety concerns and signify that carrying out long-term cardiovascular outcome trials (CVOTs) will be critical. In addition, retatrutide's potential in heart failure management is intriguing given the series of positive findings of semaglutide on cardiovascular outcomes.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543784.2023.2276754

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Research works printed but not linked: 1

  1. Collip JB. Delayed manifestation of the physiological effects of insulin following the administration of certain pancreatic extracts. Am J Physiol. 1923;63(3):391–392.

Cited by

See all 11

Metadata

Authors
Ray, A.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Ray, Avik
Venue
Expert Opinion on Investigational Drugs
Published
2023-10-31
Volume
32
Issue
11
Pages
1003-1008
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W4388023373
Cited by
11
References
55
Citations by year
2026: 4 · 2025: 5 · 2024: 2
FWCI
1.71
Type
journal article
Language
en
Open access
closed
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion)
  • PubMed (publishedVersion)
Funders
funding from any source
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
retatrutide, obesity treatment, type 2 diabetes, weight loss, HbA1c, heart failure, cardiovascular safety, cardiac arrhythmias, dulaglutide, semaglutide, gastrointestinal adverse effects
MeSH terms
Obesity Management, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Heart Failure, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Obesity, Weight Loss, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Retatrutide: a triple incretin receptor agonist for obesity management. https://app.cochat.ai/papers/10.1080/13543784.2023.2276754
The paper
Ray, A. (2023). Retatrutide: a triple incretin receptor agonist for obesity management. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2023.2276754

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.